Articles tagged with Metastasis
Researchers identified a cellular pathway by which alcohol promotes cancer progression through the activation of EMT in colon and breast cancer cells. This mechanism may contribute to the increased risk of these cancers associated with alcohol consumption.
Arizona State University scientists will study cancer cells as physical objects, examining forces, mechanical properties, and electrical properties to develop new methods for arresting tumor growth and metastasis. The goal is to understand cancer's role in the biological scheme of things and its behavior as a physical object.
The center aims to understand the explosive evolution of cancer under stress using an interdisciplinary team and physics-based approach. Researchers will create microhabitats to manipulate variables and observe cell responses, informing the development of sophisticated computer models to simulate tumor growth.
The National Cancer Institute funds a new $13 million cancer research center at Cornell University, led by Harold Craighead. The center will focus on using nanobiotechnology and other physical science approaches to advance cancer research.
Researchers discovered Snail and Twist are the major inducers of EMT in HCC, associated with reduced E-cadherin function and larger tumor size. The study provides essential information for determining liver cancer prognosis and identifying potential new treatments.
ANG1005 demonstrates disease control in over 70% of patients with progressive gliomas and brain metastases, with significant reductions in tumor size observed. The drug successfully crosses the blood-brain barrier without CNS toxicity or immunogenicity.
A case of post-gastrectomy acute pancreatitis was reported in a patient with gastric carcinoma and pancreas divisum. Early detection and aggressive treatment may improve prognosis for patients with this condition. The study highlights the importance of monitoring pancreatic function after gastrectomy.
Researchers found that a mutated FGFR4 protein is associated with advanced-stage rhabdomyosarcoma and poor survival rates. Targeting this protein may offer new treatment options for individuals with the disease.
Researchers found SRS alone reduces learning and memory problems in cancer patients with one to three brain metastases. SRS plus WBRT results in twice the risk of cognitive decline, but no survival benefit.
Researchers have identified a link between the mutated FGFR4 protein and the spread of childhood cancer. Additionally, changes in iron levels are found to affect inflammation via the TLR4 pathway, while glial cells play a crucial role in stimulating red blood cell production.
Patients with brain tumors treated with WBRT plus SRS experience significant decline in learning and memory function compared to those receiving SRS alone. The study concludes that SRS alone combined with close clinical monitoring is the preferred treatment strategy for patients newly diagnosed with one to three brain metastases.
Researchers found that SPAK silencing may promote cancer progression in B-cell lymphomas by crippling genotoxic stress signaling. In contrast, macrophage migration contributes to impaired peritoneal fluid drainage and lymphatic dysfunction in the diaphragm. Additionally, urokine plasminogen activator (uPA) is instrumental in the early ...
Researchers at Case Western Reserve University School of Medicine are investigating the role of genetic susceptibility in colon cancer metastasis. By identifying specific genes and variants, they aim to develop new anti-cancer therapies and improve patient outcomes.
Researchers found that whole-brain radiotherapy did not extend lives or improve independence in patients with limited brain metastases and stable cancer. However, it slowed cancer progression by five weeks and reduced the risk of brain-related deaths.
Researchers at UCSF have identified microRNA collections that affect distinct processes critical for cancer progression. By analyzing these 'signatures', the team found a link between deregulated microRNAs and processes like hyperproliferation, angiogenesis, and metastasis.
Researchers found that primary lung cancer shifts to metastatic disease by suppressing microRNA-200, a family of small molecules that normally locks the tumor in a noninvasive state. Protecting miR-200 from blockade completely prevented metastasis in mice.
Researchers have confirmed a link between Trichomonas vaginalis and an increased risk of prostate cancer. The study found that men infected with T. vaginalis were more likely to develop extraprostatic prostate cancer and cancer that is likely to progress to bony metastases or prostate cancer-specific death.
Researchers identified Hexokinase 2 as a key player in glucose metabolism and cell survival for breast cancer patients with brain metastases. Patients with high levels of Hexokinase 2 expression in their brain metastasis had significantly lower median survival rates compared to those with lower expression.
Researchers found that Six1 protein is central to tumor development in breast cancer, linked to EMT, stem/progenitor cells, and poor prognosis. Overexpression of Six1 also enhanced ability to metastasize, indicating its role as a key player in aggressive breast cancer.
Researchers at Albert Einstein College of Medicine have identified a distinct population of macrophages that may promote metastatic cancer growth. The study suggests that targeting these cells could inhibit tumor growth and potentially reduce cancer mortality.
New commentary published in JNCI Journal of the National Cancer Institute discusses treatment options for metastatic breast cancer. The European School of Oncology Metastatic Breast Cancer Task Force recommends sequential chemotherapy with a single agent for patients without rapid progression or life-threatening metastasis.
A study by Hoag Memorial Hospital Presbyterian found that patient-specific cancer vaccines derived from patients' own cells resulted in impressive long-term survival rates. The vaccine was well-tolerated, and eight patients experienced remarkable progression-free survival despite having widely metastatic disease.
A team of researchers at the University of Chicago has designed a computer program that uses artificial intelligence to analyze ultrasound images and predict whether a woman's breast cancer has metastasized. The pilot study, which analyzed 50 women with suspected breast cancer, found that the AI tool accurately identified 20 cases of m...
Research found that smoking increases the likelihood of pancreatic ductal adenocarcinoma becoming metastatic, with osteopontin isoform OPNc playing a key role. High levels of OPNc were detected in 87% of invasive PDA lesions from smokers, correlating with nicotine exposure.
Two matrix metalloproteinase (MMP) proteins contribute to bone metastasis in advanced breast cancer by degrading extracellular matrix and stimulating osteoclast activity. This discovery supports therapeutic targeting of MMP1 and ADAMTS1, potentially mitigating bone complications in advanced metastatic breast cancers.
A study found sunitinib to be safe and well-tolerated in patients with brain metastases, poor performance status, and elderly age groups. Median progression-free and overall survival were 10.9 and 18.4 months respectively.
A new study led by Memorial Sloan-Kettering Cancer Center researchers identifies the genetic function that enables breast cancer cells to survive and spread in the bone marrow. The findings support the development of therapies targeting this survival capacity, which could prevent metastasis and improve patient outcomes.
Researchers have identified key signals supporting long-term survival of breast cancer cells after they spread to the bone marrow. The study found that activity of a cancer-related enzyme called Src is associated with late-onset bone metastasis and promotes cell survival.
Lung cancer's rapid spread is linked to a hyperactive WNT cell-signaling pathway, enabling aggressive tumor growth and poor clinical outcomes. The study identifies two genes activated by WNT that enhance invasion and reinitiation of tumor growth in other organs.
A new three-way measurement method has been developed to predict disease metastasis in prostate cancer, combining PSA doubling time, Gleason score, and interval between surgery and detectable PSA levels. This improved prediction method may help determine which patients benefit from additional therapy after surgery.
Researchers at Max Delbrück Center for Molecular Medicine have identified 115 genes associated with metastatic potential in colorectal cancer. The study found that BAMBI gene is more active in metastatic tumors, promoting metastasis formation through key signaling pathways.
A €12 million European Union-funded study led by the University of Manchester aims to tackle tumour hypoxia, a critical factor hindering effective cancer treatment. Researchers will investigate how hypoxia affects cell behavior and develop targeted therapies to improve patient outcomes.
Researchers at Whitehead Institute for Biomedical Research discovered a microRNA, miR-31, that inversely correlates with metastasis in breast cancer. Increasing miR-31 levels can help predict patient prognoses and potentially aid in the development of targeted therapies.
The presence of multiple portal vein invasion (PVI) is a significantly poor prognostic factor for hepatocellular carcinoma. Anatomical resection is recommended for patients with HCC and PVI-M, while non-anatomical resection may lead to poorer disease-free survival.
A study published in World Journal of Gastroenterology found that patients with extrahepatic disease, high carcinoembriogenic antigen levels, or multiple nodules have poorer survival rates. Despite this, advances in surgical technique and complementary treatments are increasing the number of patients benefiting from curative treatment.
A team of scientists at The University of Texas M. D. Anderson Cancer Center has identified four new targets for breast cancer treatment, including three lysophosphatidic acid receptors and the enzyme autotaxin. These targets are found to be abnormally expressed in many types of cancer and have been shown to cause cancer.
A new study has found that autoantibodies are not strongly associated with improved outcomes in melanoma patients treated with interferon. The CAPRA score was accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality at diagnosis of localized prostate cancer.
Researchers uncover molecular mechanism that enables tumor cells to attract new blood vessels continuously in the brain, even when oxygen is still abundant. The discovery could provide a basis for therapies targeting activated integrin alpha-vbeta3 to inhibit metastatic brain disease.
A national RTOG study found that prophylactic cranial irradiation (PCI) significantly decreased the incidence of brain metastases during the first year post-treatment. Patients who received PCI were two and one-half times less likely to develop brain metastasis than those who did not.
Researchers at M.D. Anderson Cancer Center found a significant increase in median overall survival from 8 to 30 months for patients with advanced disease, and a projected five-year survival rate of over 30 percent. The study attributes the improvements to better surgical interventions and new chemotherapeutic agents.
LSUHSC researchers discovered that excessive IQGAP1 production weakens cell-to-cell contacts, promoting cell migration and invasion. The study provides insights into the prolonged activated state of Cdc42, a key protein involved in cancer spread.
Researchers at the Mayo Clinic have found a triple drug combination to be an effective and tolerable option for treating metastatic HER2+ breast cancer. The regimen, which combines capecitabine, vinorelbine, and trastuzumab, has shown promising results in reducing tumor size and improving survival rates compared to traditional treatments.
Researchers found that the gene ZBP1 is silenced in metastasizing breast cancer cells due to a methyl group attachment, leading to increased cell migration and proliferation. The study suggests potential drug targets for preventing metastasis and may help predict breast tumor outcomes by identifying signs of ZBP1 silencing.
Researchers have identified a new prognostic factor in breast cancer patients, predicting early disease recurrence, metastasis, and patient survival. The absence of caveolin-1 in the stroma is strongly associated with more aggressive disease and reduced progression-free survival.
Research at Memorial Sloan Kettering Cancer Center identifies three genes mediating breast cancer's spread to the brain. COX2 and HB-EGF prime cells for entrance, while ST6GALNAC5 enables passage through the blood-brain barrier.
Researchers are developing a strategic approach to studying metastasis, targeting the molecular and cellular players that mediate changes at future sites of metastasis. This could lead to new cancer treatments that target each step along the metastatic pathway.
Notch1 contributes to lung fibrosis by increasing myofibroblasts, while SOCS-1 inhibits prostate cancer growth. TIP30 prevents lung cancer metastasis, and SPARC accelerates kidney disease progression. These findings highlight potential new therapeutic targets.
Innate Therapeutics' novel microparticle-based immune response modifier MIS416 significantly inhibited tumor growth and metastasis in lung and breast cancers. Administered as an adjunct to localized tumor irradiation, MIS416 demonstrated synergistic activity against recurrent lung tumors.
Researchers found that brain metastases subvert astrocytes, tricking them into protecting tumors and resisting chemotherapy. Surgery is effective when tumor removal is done intact, reducing the risk of cancer spreading to the spinal fluid.
Researchers at Johns Hopkins Medicine tracked how prostate cancer began in 33 men, finding a set of genetic defects in a single cell that differ for each person's cancer. The study suggests that common genetic patterns across metastatic sites indicate a single cell source.
Scientists at Heidelberg University Hospital have identified a previously unknown protein called SCAI that inhibits the movement and spread of tumor cells. The study suggests that SCAI could be an interesting starting point for research into new mechanisms for fighting cancer.
Researchers at Mayo Clinic have discovered the molecular interplay that enables invasive tumor cells to move and invade other parts of the body. By manipulating this process, they hope to develop treatments to stop cancer from spreading.
Researchers identify TMEM density as key to predicting distant organ metastasis in breast cancer. The new marker could enable custom-tailored therapies and prevent over- or under-treatment.
The University of Texas M. D. Anderson Cancer Center has launched a new graduate program focusing on understanding and attacking cancer metastasis. The program, supported by a highly competitive grant from the University of Texas System, aims to improve basic understanding of cancer spread mechanisms.
Researchers at UVA Health System found that SRC gene promotes growth suppression in bladder cancer, contradicting its role in most cancers. The study suggests caution when using targeted therapeutic agents that inhibit SRC in bladder cancer treatment.
A new test for metastasis could help doctors precisely identify which patients should receive aggressive therapy, sparing those at low risk from unnecessary treatment. The test detects the presence of a tumor microenvironment that predicts breast cancer spread.
Researchers propose a new model explaining how cancer cells grow and spread, attributing inefficiency to pressure differences between tumor cells and host tissues. Understanding this process is crucial for developing effective treatments for metastatic cancer.
Researchers have identified a master protein that maintains epithelial cell normality and prevents cancer cells from metastasizing. The Epithelial Splicing Regulatory Protein (ESRP) plays a crucial role in regulating gene splicing, and its dysregulation can lead to cancer cell migration and tissue fibrosis.
Researchers created a mouse model of melanoma that replicates the earliest stages of skin cancer in humans. Testing two drug therapies caused a statistically significant regression in cancer cell development, offering hope for new treatment approaches.
Osteoplasty provides immediate and substantial pain relief for metastatic bone disease patients, often referred to as the 'Lazarus effect'. The procedure involves injecting bone cement into weakened bones, improving quality of life and allowing patients to resume daily activities.